Symbols / RANI Stock $0.94 +2.56% Rani Therapeutics Holdings, Inc.

Healthcare • Biotechnology • United States • NGM
RANI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Talat Imran
Exch · Country NGM · United States
Market Cap 117.27M
Enterprise Value 56.74M
Income -29.67M
Sales 1.63M
FCF (ttm) -6.79M
Book/sh 0.34
Cash/sh 0.50
Employees 69
Insider 10d —
IPO Jul 30, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.12
PEG —
P/S 71.82
P/B 2.78
P/C —
EV/EBITDA -1.52
EV/Sales 34.75
Quick Ratio 4.08
Current Ratio 4.21
Debt/Eq 10.40
LT Debt/Eq —
EPS (ttm) -0.45
EPS next Y -0.23
EPS Growth —
Revenue Growth 42.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-26
ROA -50.27%
ROE -181.98%
ROIC —
Gross Margin 100.00%
Oper. Margin -5.84%
Profit Margin 0.00%
Shs Outstand 99.81M
Shs Float 64.35M
Insider Own 5.60%
Instit Own 49.60%
Short Float 9.79%
Short Ratio 6.40
Short Interest 9.47M
52W High 3.87
vs 52W High -75.74%
52W Low 0.39
vs 52W Low 142.61%
Beta 0.66
Impl. Vol. 37.50%
Rel Volume 0.44
Avg Volume 1.10M
Volume 486.96K
Target (mean) $7.40
Tgt Median $7.00
Tgt Low $5.00
Tgt High $11.00
# Analysts 5
Recom Strong_buy
Prev Close $0.92
Price $0.94
Change 2.56%
About

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.40
Mean price target
2. Current target
$0.94
Latest analyst target
3. DCF / Fair value
$-1.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.94
Low
$5.00
High
$11.00
Mean
$7.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-01 main Canaccord Genuity Buy → Buy $5
2026-03-27 reit HC Wainwright & Co. Buy → Buy $11
2026-01-09 reit HC Wainwright & Co. Buy → Buy $11
2025-10-20 main Maxim Group Buy → Buy $10
2025-05-16 main Oppenheimer Outperform → Outperform $4
2025-04-03 reit HC Wainwright & Co. Buy → Buy $9
2025-02-26 main Canaccord Genuity Buy → Buy $9
2025-02-07 reit HC Wainwright & Co. Buy → Buy $9
2024-11-19 reit HC Wainwright & Co. Buy → Buy $9
2024-10-18 reit HC Wainwright & Co. Buy → Buy $9
2024-08-16 main HC Wainwright & Co. Buy → Buy $9
2024-08-02 init Oppenheimer — → Outperform $17
2024-06-25 reit HC Wainwright & Co. Buy → Buy $13
2024-06-14 init Maxim Group — → Buy $15
2024-06-13 init Rodman & Renshaw — → Buy $10
2024-05-09 main BTIG Buy → Buy $14
2024-05-07 main HC Wainwright & Co. Buy → Buy $13
2024-03-27 main Canaccord Genuity Buy → Buy $9
2024-03-25 main HC Wainwright & Co. Buy → Buy $12
2024-02-06 reit Wedbush Outperform → Outperform $8
News
RSS: Latest RANI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-23 IMRAN MIR A Director and Beneficial Owner of more than 10% of a Class of Security — 2,083,334 $2.09 $4,354,168
2025-10-21 SOUTH CONE INVESTMENTS L.P. Beneficial Owner of more than 10% of a Class of Security — 5,923,000 $2.41 $15,711,314
2024-12-13 MCKINLEY KATE Officer — 17,960 $1.67 $29,993
2024-12-09 IMRAN TALAT Chief Executive Officer — 10,296 $1.94 $19,974
2024-10-15 SOUTH CONE INVESTMENTS L.P. Beneficial Owner of more than 10% of a Class of Security — 3,829,360 $2.12 $8,118,243
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.63
+58.85%
1.03
0.00
0.00
Operating Revenue
1.63
+58.85%
1.03
0.00
0.00
Operating Expense
39.94
-21.10%
50.63
-23.41%
66.10
+4.17%
63.45
Research And Development
20.20
-24.27%
26.68
-32.66%
39.62
+8.24%
36.61
Selling General And Administration
19.74
-17.57%
23.95
-9.55%
26.48
-1.37%
26.84
General And Administrative Expense
19.74
-17.57%
23.95
-9.55%
26.48
-1.37%
26.84
Other Gand A
19.74
-17.57%
23.95
-9.55%
26.48
-1.37%
26.84
Total Expenses
39.94
-21.10%
50.63
-23.41%
66.10
+4.17%
63.45
Operating Income
-38.31
+22.76%
-49.60
+24.96%
-66.10
-4.17%
-63.45
Total Operating Income As Reported
-38.31
+28.14%
-53.31
+19.34%
-66.10
-4.17%
-63.45
EBITDA
-37.16
+26.45%
-50.52
+18.48%
-61.98
-0.52%
-61.66
Normalized EBITDA
-36.58
+21.85%
-46.81
+24.47%
-61.98
-0.52%
-61.66
Reconciled Depreciation
0.90
-12.45%
1.03
+25.06%
0.82
+50.00%
0.55
EBIT
-38.06
+26.17%
-51.55
+17.91%
-62.80
-0.96%
-62.20
Total Unusual Items
-0.58
+84.49%
-3.71
0.00
0.00
Total Unusual Items Excluding Goodwill
-0.58
+84.49%
-3.71
0.00
0.00
Special Income Charges
-0.58
+84.49%
-3.71
0.00
0.00
Other Special Charges
0.58
—
—
—
Impairment Of Capital Assets
—
3.71
0.00
—
Write Off
0.00
-100.00%
3.71
0.00
—
Net Income
-29.67
+1.15%
-30.02
+11.63%
-33.97
-11.06%
-30.59
Pretax Income
-40.95
+27.63%
-56.58
+16.64%
-67.88
-7.28%
-63.27
Net Non Operating Interest Income Expense
-2.06
+36.88%
-3.27
-83.30%
-1.78
-1107.91%
0.18
Interest Expense Non Operating
2.89
-42.56%
5.03
-1.02%
5.08
+374.79%
1.07
Net Interest Income
-2.06
+36.88%
-3.27
-83.30%
-1.78
-1107.91%
0.18
Interest Expense
2.89
-42.56%
5.03
-1.02%
5.08
+374.79%
1.07
Interest Income Non Operating
0.83
-53.09%
1.76
-46.59%
3.30
+164.50%
1.25
Interest Income
0.83
-53.09%
1.76
-46.59%
3.30
+164.50%
1.25
Other Income Expense
-0.58
+84.49%
-3.71
—
—
Gain On Sale Of Security
—
—
—
—
Tax Provision
—
—
0.00
-100.00%
0.07
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-40.95
+27.63%
-56.58
+16.64%
-67.88
-7.17%
-63.34
Net Income From Continuing Operation Net Minority Interest
-29.67
+1.15%
-30.02
+11.63%
-33.97
-11.06%
-30.59
Net Income From Continuing And Discontinued Operation
-29.67
+1.15%
-30.02
+11.63%
-33.97
-11.06%
-30.59
Net Income Continuous Operations
-40.95
+27.63%
-56.58
+16.64%
-67.88
-7.17%
-63.34
Minority Interests
11.28
-57.55%
26.57
-21.66%
33.91
+3.53%
32.76
Normalized Income
-29.10
-10.62%
-26.30
+22.57%
-33.97
-11.06%
-30.59
Net Income Common Stockholders
-29.67
+1.15%
-30.02
+11.63%
-33.97
-11.06%
-30.59
Diluted EPS
—
-1.05
+21.05%
-1.33
-3.91%
-1.28
Basic EPS
—
-1.05
+21.05%
-1.33
-3.91%
-1.28
Basic Average Shares
—
28.48
+11.65%
25.50
+7.09%
23.82
Diluted Average Shares
—
28.48
+11.65%
25.50
+7.09%
23.82
Diluted NI Availto Com Stockholders
-29.67
+1.15%
-30.02
+11.63%
-33.97
-11.06%
-30.59
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
58.62
+60.02%
36.63
-36.75%
57.92
-46.39%
108.03
Current Assets
53.32
+79.27%
29.74
-41.50%
50.85
-49.62%
100.92
Cash Cash Equivalents And Short Term Investments
49.71
+79.85%
27.64
-43.06%
48.54
-50.71%
98.48
Cash And Cash Equivalents
18.62
+394.90%
3.76
-35.85%
5.86
-78.29%
27.01
Other Short Term Investments
31.09
+30.21%
23.88
-44.05%
42.67
-40.29%
71.47
Receivables
2.04
+377.10%
0.43
0.00
—
Accounts Receivable
2.04
0.00
—
—
Other Receivables
—
0.43
—
—
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
—
0.50
Other Current Assets
1.57
-6.38%
1.68
-27.34%
2.31
-5.49%
2.44
Total Non Current Assets
5.30
-23.08%
6.89
-2.53%
7.07
-0.48%
7.10
Net PPE
5.05
-23.93%
6.64
-2.62%
6.82
-3.94%
7.10
Gross PPE
10.59
-6.11%
11.28
+7.53%
10.49
+5.45%
9.95
Accumulated Depreciation
-5.54
-19.40%
-4.64
-26.40%
-3.67
-28.85%
-2.85
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.33
+23.05%
0.27
+3.07%
0.26
+0.00%
0.26
Construction In Progress
0.03
+0.00%
0.03
-99.21%
3.90
-11.59%
4.42
Other Properties
8.58
-8.06%
9.33
+96.77%
4.74
+27.24%
3.73
Leases
1.66
+0.00%
1.66
+4.22%
1.59
+2.52%
1.55
Other Non Current Assets
0.25
+0.00%
0.25
+0.00%
0.25
—
Total Liabilities Net Minority Interest
17.11
-48.38%
33.14
+2.06%
32.47
-4.56%
34.02
Current Liabilities
12.67
-36.31%
19.89
+148.98%
7.99
+65.92%
4.82
Payables And Accrued Expenses
4.21
+33.57%
3.15
+48.54%
2.12
-35.19%
3.27
Payables
0.31
-77.26%
1.36
+109.72%
0.65
-57.17%
1.51
Accounts Payable
0.31
-77.26%
1.36
+109.72%
0.65
-55.62%
1.46
Current Accrued Expenses
3.90
+117.71%
1.79
+21.60%
1.47
-16.27%
1.76
Current Debt And Capital Lease Obligation
1.59
-90.36%
16.46
+193.13%
5.62
+458.15%
1.01
Current Debt
—
15.00
+206.31%
4.90
—
Other Current Borrowings
—
15.00
+206.31%
4.90
—
Current Capital Lease Obligation
1.59
+8.70%
1.46
+103.20%
0.72
-28.63%
1.01
Current Deferred Liabilities
6.83
0.00
—
—
Current Deferred Revenue
6.83
0.00
—
—
Other Current Liabilities
0.05
-83.75%
0.28
+11.42%
0.25
-52.79%
0.54
Total Non Current Liabilities Net Minority Interest
4.44
-66.49%
13.25
-45.88%
24.48
-16.17%
29.21
Long Term Debt And Capital Lease Obligation
2.73
-79.38%
13.25
-45.88%
24.48
-16.17%
29.21
Long Term Debt
—
9.61
-60.74%
24.48
-16.00%
29.15
Long Term Capital Lease Obligation
2.73
-24.88%
3.64
0.00
-100.00%
0.06
Non Current Deferred Liabilities
1.71
0.00
—
—
Non Current Deferred Revenue
1.71
0.00
—
—
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
33.01
+1557.13%
1.99
-84.52%
12.87
-65.09%
36.85
Common Stock Equity
33.01
+1557.13%
1.99
-84.52%
12.87
-65.09%
36.85
Capital Stock
0.01
+120.00%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+120.00%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
97.62
+192.02%
33.43
+28.40%
26.04
+2.93%
25.30
Ordinary Shares Number
97.62
+192.02%
33.43
+28.40%
26.04
+2.93%
25.30
Additional Paid In Capital
165.58
+57.86%
104.89
+22.30%
85.76
+13.08%
75.84
Retained Earnings
-132.58
-28.83%
-102.91
-41.18%
-72.89
-87.28%
-38.92
Gains Losses Not Affecting Retained Earnings
0.00
-80.00%
0.01
+141.67%
-0.01
+83.56%
-0.07
Minority Interest
8.50
+466.42%
1.50
-88.07%
12.58
-66.14%
37.15
Total Equity Gross Minority Interest
41.51
+1088.43%
3.49
-86.27%
25.44
-65.62%
74.00
Total Capitalization
33.01
+184.45%
11.61
-68.93%
37.35
-43.41%
66.00
Working Capital
40.65
+312.58%
9.85
-77.01%
42.86
-55.41%
96.11
Invested Capital
33.01
+24.07%
26.61
-37.03%
42.25
-35.99%
66.00
Total Debt
4.32
-85.47%
29.71
-1.30%
30.10
-0.38%
30.21
Net Debt
—
20.85
-11.34%
23.52
+997.90%
2.14
Capital Lease Obligations
4.32
-15.27%
5.10
+609.75%
0.72
-32.58%
1.06
Net Tangible Assets
33.01
+1557.13%
1.99
-84.52%
12.87
-65.09%
36.85
Tangible Book Value
33.01
+1557.13%
1.99
-84.52%
12.87
-65.09%
36.85
Derivative Product Liabilities
—
—
—
—
Dueto Related Parties Current
—
—
0.05
-1.89%
0.05
Interest Payable
0.00
-100.00%
0.93
+86.20%
0.50
+624.64%
0.07
Notes Receivable
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-18.71
+47.28%
-35.50
+30.72%
-51.24
-10.15%
-46.52
Cash Flow From Continuing Operating Activities
-18.71
+47.28%
-35.50
+30.72%
-51.24
-10.15%
-46.52
Net Income From Continuing Operations
-40.95
+27.63%
-56.58
+16.64%
-67.88
-7.17%
-63.34
Depreciation Amortization Depletion
0.90
-12.45%
1.03
+25.06%
0.82
+50.00%
0.55
Depreciation
—
—
0.80
+60.00%
0.50
Depreciation And Amortization
0.90
-12.45%
1.03
+25.06%
0.82
+50.00%
0.55
Other Non Cash Items
2.12
+3.63%
2.04
+60.33%
1.27
+51.37%
0.84
Stock Based Compensation
11.80
-26.41%
16.03
-15.66%
19.01
+20.44%
15.78
Asset Impairment Charge
0.00
-100.00%
3.71
0.00
—
Operating Gains Losses
0.74
+1043.08%
0.07
—
—
Gain Loss On Investment Securities
0.17
—
—
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.07
0.00
—
Change In Working Capital
6.96
+1379.04%
-0.54
+74.58%
-2.14
-520.43%
0.51
Change In Receivables
-1.61
-277.10%
-0.43
0.00
—
Changes In Account Receivables
-2.04
0.00
—
—
Change In Prepaid Assets
-0.19
-130.43%
0.63
+123.76%
0.28
-44.16%
0.51
Change In Payables And Accrued Expense
2.13
+101.13%
1.06
+193.48%
-1.14
-247.79%
0.77
Change In Accrued Expense
3.18
+809.71%
0.35
+164.81%
-0.54
-189.26%
0.60
Change In Payable
-1.05
-247.68%
0.71
+219.50%
-0.59
-465.03%
0.16
Change In Account Payable
-1.05
-247.68%
0.71
+219.50%
-0.59
-465.03%
0.16
Change In Other Working Capital
8.54
—
—
—
Change In Other Current Assets
—
0.00
+100.00%
-0.24
0.00
Change In Other Current Liabilities
-1.91
-5.59%
-1.81
-73.51%
-1.04
-36.39%
-0.76
Investing Cash Flow
-7.03
-135.49%
19.81
-33.66%
29.86
+141.22%
-72.44
Cash Flow From Continuing Investing Activities
-7.03
-135.49%
19.81
-33.66%
29.86
+141.22%
-72.44
Net PPE Purchase And Sale
-0.09
+67.16%
-0.27
+78.19%
-1.23
+24.09%
-1.62
Purchase Of PPE
-0.09
+67.16%
-0.27
+78.19%
-1.23
+24.09%
-1.62
Capital Expenditure
-0.09
+67.16%
-0.27
+78.19%
-1.23
+24.09%
-1.62
Net Investment Purchase And Sale
-6.94
-134.58%
20.08
-35.42%
31.09
+143.90%
-70.82
Purchase Of Investment
-33.69
+41.38%
-57.47
+21.55%
-73.26
+0.75%
-73.82
Sale Of Investment
26.75
-65.51%
77.55
-25.68%
104.35
+3378.33%
3.00
Financing Cash Flow
40.30
+196.65%
13.59
+5730.47%
0.23
-99.20%
29.00
Cash Flow From Continuing Financing Activities
40.30
+196.65%
13.59
+5730.47%
0.23
-99.20%
29.00
Net Issuance Payments Of Debt
-20.72
-314.44%
-5.00
0.00
-100.00%
29.57
Issuance Of Debt
—
—
0.00
-100.00%
29.57
Repayment Of Debt
-20.72
-314.44%
-5.00
0.00
0.00
Long Term Debt Issuance
—
—
0.00
-100.00%
29.57
Long Term Debt Payments
-20.72
-314.44%
-5.00
0.00
0.00
Net Long Term Debt Issuance
-20.72
-314.44%
-5.00
0.00
-100.00%
29.57
Net Common Stock Issuance
52.60
+188.02%
18.26
0.00
0.00
Proceeds From Stock Option Exercised
8.48
+2192.43%
0.37
-6.33%
0.40
+24.61%
0.32
Net Other Financing Charges
-0.06
-25.53%
-0.05
+70.99%
-0.16
+81.72%
-0.89
Changes In Cash
14.56
+792.48%
-2.10
+90.06%
-21.14
+76.49%
-89.95
Beginning Cash Position
4.26
-33.03%
6.36
-76.86%
27.51
-76.58%
117.45
End Cash Position
18.82
+341.53%
4.26
-33.03%
6.36
-76.86%
27.51
Free Cash Flow
-18.80
+47.43%
-35.76
+31.83%
-52.47
-9.00%
-48.13
Interest Paid Supplemental Data
2.12
-48.42%
4.11
-1.67%
4.18
+472.88%
0.73
Income Tax Paid Supplemental Data
0.00
0.00
-100.00%
0.04
-27.08%
0.05
Amortization Of Securities
-0.28
+77.71%
-1.25
+46.16%
-2.32
-172.15%
-0.85
Common Stock Issuance
52.60
+188.02%
18.26
0.00
0.00
Issuance Of Capital Stock
52.60
+188.02%
18.26
0.00
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category